Candel Therapeutics Enters Material Definitive Agreement

TL;DR

Candel Therapeutics signed a big deal, details TBD.

AI Summary

Candel Therapeutics, Inc. announced on August 18, 2025, that it entered into a material definitive agreement. The filing does not disclose specific details of the agreement or any associated financial figures.

Why It Matters

This filing indicates a significant new development for Candel Therapeutics, potentially impacting its future operations and strategic direction.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and impact of the material definitive agreement.

Key Players & Entities

• Candel Therapeutics, Inc. (company) — Registrant
• August 18, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value per share CADL The Nasdaq
• $607,880 — by the Company to the Landlord will be $607,880 per year and will increase by $15,197 a
• $15,197 — $607,880 per year and will increase by $15,197 annually during the Extended Term. Th

Filing Documents

• cadl-20250818.htm (8-K) — 46KB
• cadl-ex10_1.htm (EX-10.1) — 71KB
• 0000950170-25-110682.txt ( ) — 235KB
• cadl-20250818.xsd (EX-101.SCH) — 26KB
• cadl-20250818_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On August 18, 2025, Candel Therapeutics Inc. (the "Company") entered into a First Amendment to Lease Agreement (the "Lease Amendment"), which amends that certain Lease Agreement with 117 Kendrick DE, LLC (the "Landlord"), dated as of February 4, 2019 (the "Lease"), providing for the lease of approximately 15,197 rentable square feet in the building located at and commonly known as located at 117 Kendrick Street, Needham, Massachusetts (the "Premises"). Pursuant to the Lease Amendment, the term of the Lease was extended from August 31, 2026 to August 31, 2029 (the "Extended Term"). Under the terms of the Lease Amendment, commencing on September 1, 2026, the base rent for the Premises payable by the Company to the Landlord will be $607,880 per year and will increase by $15,197 annually during the Extended Term. The foregoing summary of the material terms of the Lease Amendment does not purport to be a complete description of the Lease Amendment and is qualified in its entirety by reference to the complete text of the Lease Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1* First Amendment to Lease of Premises at 117 Kendrick Street, Needham, Massachusetts by and between 117 Kendrick DE, LLC and the Registrant dated as of August 18, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Portions of this exhibit have been omitted by means of redacting a portion of the text and replacing it with "[***]" because they are both (i) not material and (ii) the type of information that the registrant treats as private or confidential.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Candel Therapeutics, Inc. Date: August 21, 2025 By: /s/ Paul Peter Tak Paul Peter Tak, M.D., Ph.D., FMedSci President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR